Age at onset and Parkinson disease phenotype

Neurology

Volumn 86, Issue 15, 2016, Pages 1400-1407

  Pagano, Gennaro ^a,b   Ferrara, Nicola ^b,c   Brooks, David J ^a,d   Pavese, Nicola ^a,d  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c IRCCS   (Italy)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; IOFLUPANE I 123; TAU PROTEIN; URIC ACID; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; SNCA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRADYKINESIA; CEREBROSPINAL FLUID; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; EDUCATIONAL STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NIGRONEOSTRIATAL SYSTEM; ONSET AGE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; RIGIDITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM; TREMOR; URIC ACID BLOOD LEVEL; BLOOD; CAUDATE NUCLEUS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; FACTUAL DATABASE; HEMISPHERIC DOMINANCE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PUTAMEN; SEVERITY OF ILLNESS INDEX; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY;

AGE OF ONSET; AGED; ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; BIOMARKERS; CAUDATE NUCLEUS; DATABASES, FACTUAL; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PHENOTYPE; PHOSPHORYLATION; PUTAMEN; SEVERITY OF ILLNESS INDEX; TAU PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; URIC ACID;

EID: 84964845283     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002461     Document Type: Article

References (29)

1. Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA. Heterogeneity of Parkinsons disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005;76:343-348.
2. Eggers C, Pedrosa DJ, Kahraman D, et al. Parkinson subtypes progress differently in clinical course and imaging pattern. PLoS One 2012;7:e46813.
3. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinsons disease. Brain 2009;132:2947-2957.
4. Parkkinen L, OSullivan SS, Collins C, et al. Disentangling the relationship between Lewy bodies and nigral neuronal loss in Parkinsons disease. J Parkinsons Dis 2011;1:277-286.
5. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinsons disease: a systematic review and meta-analysis. Mov Disord 2014;29:1583-1590.
6. Kish SJ, Shannak K, Rajput A, Deck JH, Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinsons disease. J Neurochem 1992;58:642-648.
7. de Lau LM, Breteler MM. Epidemiology of Parkinsons disease. Lancet Neurol 2006;5:525-535.
8. Kempster PA, OSullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinsons disease: a clinico-pathological study. Brain 2010;133:1755-1762.
9. Critchley M. The neurology of old age. Lancet 1931;1: 1221-1230.
10. Wickremaratchi MM, Ben-Shlomo Y, Morris HR. The effect of onset age on the clinical features of Parkinsons disease. Eur J Neurol 2009;16:450-456.
11. Quinn N, Critchley P, Marsden CD. Young onset Parkinsons disease. Mov Disord 1987;2:73-91.
12. Gomez Arevalo G, Jorge R, Garcia S, Scipioni O, Gershanik O. Clinical and pharmacological differences in early- versus late-onset Parkinsons disease. Mov Disord 1997;12:277-284.
13. Wickremaratchi MM, Perera D, OLoghlen C, et al. Prevalence and age of onset of Parkinsons disease in Cardiff: a community based cross sectional study and meta-analysis. J Neurol Neurosurg Psychiatry 2009;80:805-807.
14. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinsons disease revisited clinical features, natural history, and mortality. Mov Disord 1998;13:885-894.
15. Golbe LI. Young-onset Parkinsons disease: a clinical review. Neurology 1991;41:168-173.
16. Wickremaratchi MM, Knipe MD, Sastry BS, et al. The motor phenotype of Parkinsons disease in relation to age at onset. Mov Disord 2011;26:457-463.
17. Mehanna R, Moore S, Hou JG, Sarwar AI, Lai EC. Comparing clinical features of young onset, middle onset and late onset Parkinsons disease. Parkinsonism Relat Disord 2014;20:530-534.
18. Szewczyk-Krolikowski K, Tomlinson P, Nithi K, et al. The influence of age and gender on motor and non-motor features of early Parkinsons disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism Relat Disord 2014;20:99-105.
19. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011;95:629-635.
20. Post B, Speelman JD, de Haan RJ; CARPA-study group. Clinical heterogeneity in newly diagnosed Parkinsons disease. J Neurol 2008;255:716-722.
21. Kang JH, Irwin DJ, Chen-Plotkin AS, et al; Parkinsons Progression Markers Initiative. Association of cerebrospinal fluid b-amyloid 1-42, T-tau, P-tau181, and a-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;70:1277-1287.
22. Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinsons disease. Mov Disord 2014;29:454-462.
23. Marras C, Lang A. Parkinsons disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry 2013;844:409-415.
24. van der Hoorn A, Burger H, Leenders KL, de Jong BM. Handedness correlates with the dominant Parkinson side: a systematic review and meta-analysis. Mov Disord 2012; 27:206-210.
25. de la Fuente-Fernández R, Kishore A, Calne DB, Ruth TJ, Stoessl AJ. Nigrostriatal dopamine system and motor lateralization. Behav Brain Res 2000;112:63-68.
26. Vidailhet M, Bonnet AM, Marconi R, Gouider-Khouja N, Agid Y. Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot? Neurology 1994;44: 1613-1616.
27. Dickson JM, Grunewald RA. Somatic symptom progression in idiopathic Parkinsons disease. Parkinsonism Relat Disord 2004;10:487-492.
28. Rowland T, Chan HC, Brooks DJ, Pavese N. Progression of nigrostriatal projection functional loss through the striatum in Parkinsons disease: a clinico-PET correlation. MDS 17th International Congress of Parkinsons Disease and Movement Disorders, Volume 28; June 2013. Abstract Supplement.
29. Yurkovich M, Avina-Zubieta JA, Thomas J, Gorenchtein M, Lacaille D. A systematic review identifies valid comorbidity indices derived from administrative health data. J Clin Epidemiol 2015;68:3-14.